Table 2.
Proportion of patents and dispensed antihypertensive drug classes according to comorbidity
| ACEIs | ARBs | CCBs | β‐Blockers | Diuretics | MRAs | |
|---|---|---|---|---|---|---|
| Women | ||||||
| No cardiovascular disease | 25.0 (24.8–25.3) | 29.4 (29.1–29.7) | 27.6 (27.3–27.8) | 30.5 (30.2–30.8) | 34.7 (34.4–35.1) | 1.6 (1.5–1.7) |
| Ischemic heart disease | 29.9 (29.2–30.6) | 30.3 (29.6–30.9) | 32.3 (31.6–33.0) | 68.0 (67.3–68.7) | 49.6 (48.8–50.5) | 7.3 (7.0–7.7) |
| Atrial fibrillation | 29.7 (28.9–30.4) | 30.3 (29.6–31.1) | 28.0 (27.3–28.7) | 76.5 (75.8–77.1) | 59.5 (58.5–60.4) | 11.3 (10.8–11.8) |
| Congestive heart failure | 36.335.4–37.1) | 29.9 (29.1–30.8) | 25.1 (24.3–25.9) | 69.6 (68.7–70.4) | 73.672.6–74.6) | 17.3 (16.6–17.9) |
| Cerebrovascular disease | 30.3 (29.3–31.3) | 27.2 (26.2–28.2) | 32.8 (31.8–33.8) | 49.6 (48.2–50.3) | 44.5 (43.4–45.7) | 5.5 (5.0–6.0) |
| Diabetes mellitus | 35.7 (35.1–36.2) | 36.4 (35.8–37.1) | 34.6 (34.0–35.2) | 46.3 (45.6–46.8) | 50.4 (49.8–51.2) | 5.3 (5.0–5.6) |
| Men | ||||||
| No cardiovascular disease | 34.3 (33.9–34.6) | 28.6 (28.3–28.9) | 32.3 (32.1–32.7) | 24.524.2–24.8) | 27.9 (27.6–28.3) | 1.1 (1.0–1.2) |
| Ischemic heart disease | 42.9 (42.3–43.6) | 27.6 (27.0–28.2) | 31.6 (31.0–32.2) | 71.9 (71.3–72.4) | 37.5 (36.8–38.1) | 6.7 (6.4–7.1) |
| Atrial fibrillation | 40.1 (39.4–40.9) | 28.9 (28.3–29.6) | 31.6 (30.9–32.2) | 72.6 (71.9–73.2) | 48.4 (47.5–49.2) | 9.9 (9.4–10.3) |
| Congestive heart failure | 48.1 (47.1–48.9) | 28.1 (27.3–28.8) | 25.6 (24.8–26.4) | 73.2 (72.4–74.0) | 63.5 (62.5–64.6) | 19.2 (18.5–19.9) |
| Cerebrovascular disease | 40.7 (39.7–41.7) | 25.4 (24.5–26.4) | 35.3 (34.3–36.3) | 47.5 (46.5–48.5) | 37.0 (35.9–38.1) | 5.1 (4.7–5.6) |
| Diabetes mellitus | 46.4 (45.8–46.9) | 32.2 (31.8–32.8) | 38.2 (37.7–38.8) | 46.3 (45.8–46.7) | 43.9 (43.4–44.6) | 5.3 (5.0–5.5) |
Proportions of patients are presented as percentages with 95% confidence intervals, according to comorbidity. Cerebrovascular disease includes transient ischemic attack and stroke. No cardiovascular disease is defined as patients with hypertension with no ischemic heart disease, atrial fibrillation, congestive heart failure, or cerebrovascular disease. Abbreviations: ACEIs, angiotensin‐converting enzyme inhibitors; ARBs, angiotensin receptor blockers; CCBs, calcium channel blockers; MRAs, mineralocorticoid receptor antagonists.